行政首长在季度亏损和收入不断下降的情况下出售了17 000多股股票。 Executives sold over 17,000 shares amid quarterly loss and declining revenue.

Arcus生物科学内部人士,包括CFO Alexander Azoy、CO Jennifer Jarrett和Richard Markus总统,在2025年12月底总共出售了17 000多股股份,收益总额约为310 000美元。 Arcus Biosciences insiders, including CFO Alexander Azoy, COO Jennifer Jarrett, and President Richard Markus, sold a combined total of over 17,000 shares in late December 2025, with proceeds totaling approximately $310,000. 销售价格在21.88美元至26.00美元之间,大大降低了它们的股份。 The sales occurred at prices between $21.88 and $26.00, reducing their stakes significantly. 该公司报告说,每股损失1.27美元,估计损失额为每股1.3格查尔,尽管年收入比上一年下降45.8%,降至2 600万美元。 The company reported a Q3 loss of $1.27 per share, beating estimates, though revenue fell 45.8% year-over-year to $26 million. Arcus Biosciences(Arcus Birosciences)是一家发展癌症治疗的临床阶段生物制药公司,市场上限为23.8亿美元,协商一致的“Moderate Buy”评级为“Moderate Buy”,目标价为28.89美元。 Arcus Biosciences, a clinical-stage biopharma firm developing cancer therapies, has a market cap of $2.38 billion and a consensus "Moderate Buy" rating with a target price of $28.89. 12月18日,库存以22.02美元关闭,减少了0.26美元。 The stock closed at $22.02 on December 18, down $0.26.